Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO

Release time:2019-06-05

From May 31 to June 4, 2019, a prestigious international event on cancer, the American Society of Clinical Oncology (ASCO) 2019 annual meeting was officially held at the McCormick Exhibition Center in Chicago, USA. During the period, Genetron Health showcased its remarkable research results on breast cancer together with the Human Longevity Inc (HLI) from the United States at the ASCO exhibition, and has discussed the latest research progress with the experts, scholars and partners there.


Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO


Intensify basic researches and strengthen the whole life cycle cancer testing service


Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO


Profound basic research capability have always been the powerhouse of the continuous advancement of Genetron Heathl. In the ASCO conference, the research results on gene mutations in early-onset breast cancer by Genetron Health and National Cancer Center team lead by Professor Fei Ma were also selected. By comparing the sequence of hundreds of women with early-onset breast cancer and control group, the team found that PTCH family gene-specific mutation may be a cause in early-onset breast cancer, and with a poor prognosis. To further explore its functional and molecular mechanisms, the research team tested at the molecular, cellular, and animal levels, respectively, with the result suggesting that it may be a biomarker for the diagnosis and prognosis biomarker of early-onset breast cancer.


Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO


As a pioneer in precise diagnosis and treatment of cancer, Genetron Health has taken root in the basic research of cancer genomics, and published more than 20 papers in international authoritative academic journals such as Nature Genetics, Cancer Cell, Nature Communications and PNAS. The published papers cover the whole cycle of cancer such as genetic susceptibility, early screening, molecular pathological diagnosis, medication guidance, prognosis monitoring, etc. The research fields cover high-risk lung cancer, liver cancer, colorectal cancer, stomach cancer, thyroid cancer, breast cancer, brain tumor and urinary system cancer. Genetron Health is gradually making breakthroughs in difficulties such as liquid biopsy, and scoring many milestones.


Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO


Integrated service system to explore a new partnership model with international pharmaceutical company


Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO


During the conference, Genetron Health and HLI teamed up to bring the “integrated drug research and development system”, and conducted many exchanges and negotiations with international pharmaceutical companies, who unanimously recognized Genetron Health's contribution.


Harvesting innovation, expanding to the world – Genetron Health in the 2019 ASCO


Relying on diversified detection platform, self-developed bio-information analysis platform, huge detection database, multi-disciplinary talent team and professional service, the two sides have outstanding strength in the following three areas: NGS platform based WES and large Panel product development, digital PCR and real-time fluorescent quantitative PCR detection product development platform, 'one-step' detection method and other innovative technologies. The two sides can simultaneously provide integrated services ranging from target screening, clinical trial design and implementation, companion diagnostic (CDx), and real world research (RWS) for multinational pharmaceutical companies, innovative pharmaceutical companies, and biomedical CRO partners. This service system breaks the dilemma of cross-border drug development cooperation and provides standardized clinical trial services which can be registered in both China and the United States.


At present, Genetron Health has successively cooperated with many outstanding enterprises from home and abroad such as Casipharma, AstraZeneca, EdiGene, Juventas Bio, HLI, etc. to stretch to the upstream and downstream of the global industrial chain.


Summary


Be it the intensive basic research, the precise R&D of innovative drugs, and the clinical research of individualized diagnosis and treatment methods, it is essential to have the unremitting efforts of hospitals, experts and enterprises. Although the road to fight cancer is long and bumpy, as the theme of 2019 ASCO Meeting “Caring for Every Patient, Learning from Every Patient” states, Genetron Health will always practice the values of “Taking responsibility for the health and life of others”. Through cooperation and learning from others, we will deepen the whole-cycle cancer service system and effectively promote the development of precision medicine.


COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
犀牛云提供云计算服务
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Verification code:
Genetron Health Genetron Health Management